News & Media
February 8, 2022
Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing
Gene therapies offer an unprecedented ability to treat — and even cure — genetic diseases, and their potential spanning diverse...
January 13, 2022
FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development
COLUMBUS, OH, January 13, 2022 – Andelyn Biosciences, a pioneering cell and gene therapy CDMO born out of Nationwide Children’s Hospital, today...
November 22, 2021
Nationwide Children’s Spinoff Andelyn Biosciences to Open New Lab in Dublin
Andelyn Biosciences has set its sights on Dublin for one of two new labs for the gene therapy company.
November 11, 2021
Leveraging Partnerships and a Unique History to Address Supply Chain and Capacity Challenges in Gene Therapy Manufacturing
Andelyn Biosciences has established a unique network of industry experts across the entire development and commercialization spectrum. In addition to...
October 22, 2021
Coping with a Talent Shortage and Talent War in Cell and Gene Therapy
Andelyn Biosciences is building the best cell and gene therapy team in spite of a talent shortage and competitive talent...
September 30, 2021
Gene therapy manufacturer Andelyn adds lab in Dublin as construction continues in OSU Innovation District
Andelyn Biosciences Inc. is adding a second laboratory in Dublin, and will move into its headquarters in Ohio State University's Innovation District before construction is complete.
September 23, 2021
Navigating Analytical Requirements for GMP Viral Vectors
The analytical requirements for viral vectors used to deliver gene therapies are complex and constantly evolving. The keys to success,...
September 16, 2021
Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing
The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of...
August 25, 2021
Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing
TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers.
August 23, 2021
Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances
Abstract: Andelyn Biosciences, a full-spectrum gene therapy CDMO organization that supports clients from preclinical studies through phase III trials, originally...